Can a Simple Blood Test Catch Eye Cancer Spread Early?

In Plain English

This study is looking for a way to catch uveal melanoma before it spreads to other parts of your body—or catch it very early if it does spread. Right now, doctors use imaging scans (like CT or MRI) to find metastases (cancer that has spread), but by the time those show up, the cancer may already be advanced. The researchers believe that cancer cells release tiny chemical signals into your bloodstream when they start to spread. If doctors can detect these signals with a simple blood test, they might catch metastases months or even years earlier than imaging can—when surgery to remove them could give you 10+ years of life instead of just 7-12 months. You'll have blood drawn regularly so researchers can measure these biomarkers over time. They're testing several different markers to see which ones are most reliable at predicting or detecting metastatic disease. This isn't a treatment—it's a diagnostic study to develop a better early warning system for you and other uveal melanoma patients.

What This Trial Does

Uveal melanoma is the most common primary intraocular tumor in adults. The local treatment is effective, but patients still die of metastatic disease. It has been shown that early diagnosis of a few isolated metastases can result in a clean surgical excision of the metastases and an extension of the expected survival from 7-12 months to over 10 years on some patients. Many serum biomarkers are employed in Oncology. It makes sense to try the relevant ones in the diagnosis of metastatic uveal melanoma. The investigators hypothesis is that a soluble serum biomarker level changes upon development of metastatic disease either by secretion by the tumor cells themselves or by their environment. Detection of changes in biomarker level may lead to the diagnosis of metastases before they can be detected by imaging modalities, thus allowing for early treatment of the metastases and a better chance of success.

Who Can Join